On November 10, Viking Therapeutics rose 8.16% in Regular Trading, trading at $29.01/share, with turnover of $63.90 million.
The most recent company-specific backdrop in public reporting was the late-October update showing a third-quarter EPS loss of $1.55, wider than consensus expectations, alongside positive study data and a cash, cash equivalents, and short-term investments balance of about $960 million. That combination supported investor attention on the company’s ability to keep advancing its obesity pipeline despite near-term earnings pressure.
Recent developments also included the start of the Phase 3 program for oral VK2735 in adults with obesity and earlier maintenance-dosing data indicating that less frequent VK2735 dosing preserved a high proportion of prior weight loss, reinforcing the competitive profile of the lead obesity candidate.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments